Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12243063 | 0.94 | DNM1 (0.43) | TSHRLMNADNM1CA12CA1 | |
| SCHEMBL7776810 | 0.94 | DNM1 (0.32) | TSHRLMNADNM1CA12CA1 | |
| SCHEMBL26502986 | 0.92 | DNM1 (0.48) | TSHRLMNADNM1CA12CA1 | |
| SCHEMBL26502982 | 0.92 | DNM1 (0.48) | TSHRLMNADNM1CA12CA1 | |
| SCHEMBL13152919 | 0.91 | DNM1 (0.46) | TSHRLMNADNM1CA12CA1 | |
| SCHEMBL10705836 | 0.88 | DNM1 (0.50) | TSHRLMNADNM1CA12CA1 | |
| Nonane SCHEMBL28466423 | 0.88 | DNM1 (0.50) | TSHRLMNADNM1CA12CA1 | |
| SCHEMBL14997774 | 0.88 | DNM1 (0.50) | TSHRLMNADNM1CA12CA1 | |
| SCHEMBL14997773 | 0.88 | DNM1 (0.50) | TSHRLMNADNM1CA12CA1 | |
| SCHEMBL7770548 | 0.88 | CA12 (0.33) | TSHRLMNADNM1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-27 | — | — | US | disclosed |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-27 | — | — | US | disclosed |
| US-20230399290-A1 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | PTC INNOVATIONS LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399292-A1 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | PTC Innovations, LLC | 2023-12-14 | — | — | US | disclosed |
| US-20230399291-A1 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | PTC INNOVATIONS LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11814335-B1 | Anesthetic compounds and methods of making and using same to treat or prevent pain symptoms | PTC Innovations, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| CN-102884039-A | Method for producing unsymmetrical secondary tert-butyl amines in the gas phase | BASF SE | 2013-01-16 | — | — | CN | disclosed |
| WO-2011124577-A1 | METHOD FOR PRODUCING UNSYMMETRICAL SECONDARY TERT-BUTYL AMINES IN THE GAS PHASE | BASF SE (DE) | 2011-10-13 | — | — | WO | disclosed |
| US-20110251434-A1 | PROCESS FOR PREPARING UNSYMMETRIC SECONDARY TERT-BUTYLAMINES IN THE GAS PHASE | BASF SE (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20110229581-A1 | RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-7528163-B2 | N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye | MERCK & CO. INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7365093-B2 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-7208517-B1 | Endothelin antagonists | ABBOTT LABORTORIES (US) | 2007-04-24 | — | — | US | disclosed |
| EP-0838508-B1 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORP (JP) | 2001-08-29 | — | — | EP | disclosed |
| US-5871572-A | COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID | SEIKO EPSON CORPORATION (JP) | 1999-02-16 | — | — | US | disclosed |
| EP-0838508-A2 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORPORATION (JP) | 1998-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251434-A1 | PROCESS FOR PREPARING UNSYMMETRIC SECONDARY TERT-BUTYLAMINES IN THE GAS PHASE | TERT, PNMT, ADH5 | TSHR 1149/4885LMNA 798/4885DNM1 3857/4885 |
| US-20230399290-A1 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | OPRK1, ACHE, F5 | TSHR 2954/4885LMNA 2285/4885DNM1 4100/4885 |
| US-20230399292-A1 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | OPRM1, OPRL1, OPRK1 | TSHR 1465/4885LMNA 2668/4885DNM1 2591/4885 |
| US-20230399291-A1 | ANESTHETIC COMPOUNDS AND METHODS OF MAKING AND USING SAME TO TREAT OR PREVENT PAIN SYMPTOMS | CHRM2, RXFP2, OPRM1 | TSHR 2336/4885LMNA 3130/4885DNM1 2355/4885 |
| US-20110229581-A1 | RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | APLNR, LPAR6, ABHD16A | TSHR 2121/4885LMNA 467/4885DNM1 448/4885 |
| US-11814335-B1 | Anesthetic compounds and methods of making and using same to treat or prevent pain symptoms | F8, F5, OPRM1 | TSHR 2702/4885LMNA 2286/4885DNM1 4333/4885 |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | TSHR 2262/4885LMNA 350/4885DNM1 307/4885 |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, NPC1L1, NPC1 | TSHR 3323/4885LMNA 284/4885DNM1 487/4885 |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | PNLIP, LIPA, PHOSPHO1 | TSHR 2016/4885LMNA 164/4885DNM1 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.